Navigation Links
PulmoBioTech Announces Details of Its Regulatory Approval Experiments
Date:4/24/2008

NEW YORK, April 24 /PRNewswire-FirstCall/ -- PulmoBioTech Inc. (OTC Bulletin Board: PLMO) announced today that its PulmoScience subsidiary has released details of the areas that it will be investigating as part of the Regulatory Approval Experiments for Human Trials. The areas are:

1. Efficacy Binding Studies

2. Characterization of Drug Product Impurities

3. Sterility Studies

4. Pyrogenicity

5. Immunological Testing

6. Dosimetry

7. Toxicity

PulmoScience will be completing all the relevant tests in each area and seeking Regulatory sign-off before starting the detailed Human Trials. This is currently expected to be achieved in the first half of 2008.

About PulmoBioTech Inc.

PulmoBioTech Inc. specializes in the development and marketing of medical technology and research. Our proven strengths combine extensive commercial experience and academic credentials. The principal staff members are acknowledged experts in their specialized field, and work with a broad range of investment institutions. PulmoBioTech's mission is to utilize scientific imagination and drive, together with managerial and financial acumen, to bring innovative and profitable products to the marketplace to the benefit of all stock holders.

About PulmoScience Inc.

PulmoScience Inc. was established in 2006, and is currently developing a non-invasive Molecular Imaging technique for the diagnosis of Pulmonary Embolism, Pulmonary Hypertension and Lung Inflammatory diseases under the trade name PulmoBind.

The company was conceived within the Montreal Heart Institute "MHI" (a world renowned hospital and educational facility). Jointly owned by MHI subsidiary Innovacor as the technical and operational partner, Dr. Jocelyn Dupuis (the scientific director and originator of the PulmoBind Molecular Imaging technology), and by PulmoBioTech Inc. as the funding partner, PulmoScience Inc. aims to develop this unique and ex
'/>"/>

SOURCE PulmoBioTech Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... LA JOLLA, Calif. , May 21, 2013 /PRNewswire/ ... a biopharmaceutical company leading the discovery and development of ... Garry E. Menzel , Ph.D., Chief Operating Officer ... overview at the Deutsche Bank 38th Annual Healthcare Conference ... The conference is being held at the Westin Boston ...
(Date:5/21/2013)... (NASDAQ: LCAV ), a leading provider of laser ... that all nominees to the company,s Board of Directors were ... These Directors are: , William F. Bahl ... Counsel , John C. Hassan , ... Heizer III , Chairman of Manus Health Systems, Inc. ...
(Date:5/21/2013)... 21, 2013  Zacks.com announces the list of stocks ... Equity Research analysts discuss the latest news and events ... in the blog include Actavis, Inc.,s (NYSE: ACT ... (NYSE: TOT ), Petrobras (NYSE: PBR ) ... (Logo: http://photos.prnewswire.com/prnh/20101027/ZIRLOGO ) Get ...
Breaking Medicine Technology:Regulus to Present at Deutsche Bank 38th Annual Healthcare Conference 2LCA-Vision Reports on Annual Meeting of Stockholders 2LCA-Vision Reports on Annual Meeting of Stockholders 3LCA-Vision Reports on Annual Meeting of Stockholders 4The Zacks Analyst Blog Highlights: Actavis, BP, Total, Petrobras and Devon Energy 2The Zacks Analyst Blog Highlights: Actavis, BP, Total, Petrobras and Devon Energy 3The Zacks Analyst Blog Highlights: Actavis, BP, Total, Petrobras and Devon Energy 4The Zacks Analyst Blog Highlights: Actavis, BP, Total, Petrobras and Devon Energy 5
... 2011 OrbusNeich today announced that 12-month follow-up data from ... ccelerated L ining I nhibits N eointimal ... EuroIntervention demonstrated good clinical outcomes with ... the company,s Genous Stent. Target vessel failure (TVF), ...
... school hockey coach is taking the pro-active approach to ... coaches at Stevenson High School, invented the Shockwave ... risk of sustaining a concussion, including athletes, firefighters and ... is a three-step system, starting with baseline testing to ...
Cached Medicine Technology:Published Data From e-HEALING Registry Demonstrate Good Clinical Outcomes With Low Incidence of Repeat Revascularization and Stent Thrombosis for OrbusNeich's Genous™ Stent 2Published Data From e-HEALING Registry Demonstrate Good Clinical Outcomes With Low Incidence of Repeat Revascularization and Stent Thrombosis for OrbusNeich's Genous™ Stent 3Shockwave System Developed to Aid Concussion Detection 2
(Date:5/21/2013)... 21, 2013 Parker Waichman LLP, a ... victims injured by defective medical devices, is addressing new ... Surgery on May 15, 2013. The study found that ... complications that occur in patients with metal-on-metal hip implants ... http://www.jbjs.org/article.aspx?articleid=1684770 ) , “We’ve known for ...
(Date:5/21/2013)... CA (PRWEB) May 21, 2013 ... Annual EB-5 Investment Summit: Dealmakers Conference in Long ... Conference will focus on exploring alternative finance through ... the latest market, legal and economic information, and ... and legal professionals within the EB-5 industry. ...
(Date:5/21/2013)... AZ (PRWEB) May 21, 2013 ... and inventors who want to develop their ideas ... summer program. , The university is recruiting ... revolutionary new “formation space” that provides early-stage entrepreneurs ... While AREA48 is open to anyone, ASU is ...
(Date:5/21/2013)... 2013 The In View series ... and cable channels across the country, announces it has ... channel. The producers of the series proudly bring audiences ... industry, the manufacturing industry, health-related companies, medical facilities and ... medical practitioners in all parts of the United States, ...
(Date:5/21/2013)... May 21, 2013 Global Proving Ground ... Bodybuilding.com, the largest online retailer of health and fitness ... reality-based sports show, Warrior Island. “We cast the ... Facebook & Twitter, with our unique social networking platform,” ... these elite fighters on an island in the Pacific ...
Breaking Medicine News(10 mins):Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 2Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 3Health News:Artisan Business Group to Host EB-5 Investment Conference in Long Beach, California 2Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 2Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 3Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 4Health News:In View hosted by Larry King Announces New Videos on its YouTube Channel 2Health News:Bodybuilding.com Partners with Global Proving Ground’s New Reality Show Warrior Island 2Health News:Bodybuilding.com Partners with Global Proving Ground’s New Reality Show Warrior Island 3
... Colorado that involves door-to-door counseling in low-income Hispanic ... and "is raising questions about whether different strategies ... the Denver Rocky Mountain News reports. ... increase, which so far directed $61 million to ...
... time, physician-scientists at NewYork-Presbyterian Hospital/Weill Cornell Medical Center in ... of an antibody to directly target the blood supply ... unharmed. ,The Phase I clinical trial tested ... membrane antigen (PSMA). ,PSMA has been an ...
... participation in a national study, patients being treated ... at North Shore University Hospital// (NSUH) and Long ... that an arsenic compound, coupled with standard chemotherapy ... all had newly-diagnosed acute promyelocytic leukemia, or APL, ...
... first time have used stem cells from the hair follicles ... is much more efficient than the other existing procedures and ... ,This study was undertaken by a team from Laboratory of ... York City and was published in the current issue of ...
... standard breast cancer therapy drug tamoxifen, to another one exemestane//, ... Publishing their findings in the online version of The Lancet, ... UK, and team, stood for changing treatments tracks to exemestane ... it reduced deaths by 17 percent. ,Their findings ...
... who develop lung cancer as 10 to 15 percent//. ... offer support to these estimates, in the form of similar ... of Oncology, Dr. Heather Wakelee of Stanford University in California ... lung cancer patients are women who have never smoked. ...
Cached Medicine News:Health News:First Treatment to Directly Target Tumor Blood Supply 2Health News:First Treatment to Directly Target Tumor Blood Supply 3Health News:Arsenic Compound Effective in Treating Rare Leukemia 2Health News:Arsenic Compound Effective in Treating Rare Leukemia 3Health News:New Drug Therapy for Breast Cancer Offers Hope 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: